Tivic Health Systems Inc
TIVC0.890USD
+0.032+3.72%
Horário de mercado （ET）Cotações atrasadas em 15 min
1.48MValor de mercado
PerdaP/L TTM
Mais detalhes de Tivic Health Systems Inc Empresa
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Informações de Tivic Health Systems Inc
Código da empresaTIVC
Nome da EmpresaTivic Health Systems Inc
Data de listagemNov 11, 2021
CEOErnst (Jennifer)
Número de funcionários7
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 11
Endereço47685 Lakeview Blvd
CidadeFREMONT
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94538
Telefone18882766888
Sitehttps://tivichealth.com/
Código da empresaTIVC
Data de listagemNov 11, 2021
CEOErnst (Jennifer)
Executivos da empresa Tivic Health Systems Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+9444.00%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Mr. Michael K. Handley
Mr. Michael K. Handley
Chief Operating Officer and President of Tivic Biopharma
Chief Operating Officer and President of Tivic Biopharma
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Jennifer Ernst
Ms. Jennifer Ernst
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
32.69K
+9444.00%
Ms. Sheryle J Bolton
Ms. Sheryle J Bolton
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Dean Zikria
Mr. Dean Zikria
Independent Director
Independent Director
--
--
Mr. Jim Hock
Mr. Jim Hock
Investor Relations
Investor Relations
--
--
Ms. Lisa Wolf
Ms. Lisa Wolf
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Christina Valauri
Ms. Christina Valauri
Independent Director
Independent Director
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: dom, 11 de jan
Atualizado em: dom, 11 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Avenue Capital Group
4.02%
DRW Securities, LLC
2.14%
Marex Group plc
1.52%
Ernst (Jennifer)
1.29%
UBS Financial Services, Inc.
0.78%
Outro
90.25%
Investidores
Investidores
Proporção
Avenue Capital Group
4.02%
DRW Securities, LLC
2.14%
Marex Group plc
1.52%
Ernst (Jennifer)
1.29%
UBS Financial Services, Inc.
0.78%
Outro
90.25%
Tipos de investidores
Investidores
Proporção
Investment Advisor
4.51%
Investment Advisor/Hedge Fund
4.33%
Individual Investor
1.31%
Research Firm
0.06%
Outro
89.79%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
22
224.75K
8.90%
+144.85K
2025Q3
22
44.96K
2.86%
+5.91K
2025Q2
32
112.57K
10.82%
+62.79K
2025Q1
32
1.24K
0.18%
-48.58K
2024Q4
34
288.82K
2.82%
-516.93K
2024Q3
32
301.13K
4.87%
-468.33K
2024Q2
32
639.36K
10.34%
+419.46K
2024Q1
34
88.08K
6.01%
-141.85K
2023Q4
34
75.33K
5.40%
-149.34K
2023Q3
33
160.42K
18.20%
+130.18K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Avenue Capital Group
101.64K
5.76%
+101.64K
--
Sep 30, 2025
DRW Securities, LLC
53.94K
3.05%
+53.94K
--
Sep 30, 2025
Marex Group plc
38.39K
2.17%
-890.00
-2.27%
Sep 30, 2025
Ernst (Jennifer)
32.69K
1.85%
+9.44K
+40.62%
Dec 18, 2025
UBS Financial Services, Inc.
801.00
0.05%
-4.85K
-85.83%
Sep 30, 2025
Geode Capital Management, L.L.C.
5.07K
0.29%
--
--
Nov 30, 2025
The Vanguard Group, Inc.
1.94K
0.11%
--
--
Nov 30, 2025
Citi Investment Research (US)
1.43K
0.08%
+1.43K
--
Sep 30, 2025
Wolf (Lisa G)
434.00
0.02%
+434.00
--
Dec 18, 2025
SBI Securities Co., Ltd.
16.00
0%
--
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Data
Data ex-dividendo
Tipo
Proporção
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Mar 05, 2025
Merger
17→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
Aug 22, 2023
Merger
100→1
